Want to see AU:IVX full AI Analyst Report?
Top Page
Invion
(Sydney:IVX)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.04
▼(-2.50% Downside)
Action:Reiterated
Date:07/28/26
The score is driven primarily by very weak financial performance (zero revenue in FY2025, widening losses, and continued cash burn) despite a debt-free balance sheet. Technicals provide only modest support, with the share price above short-term averages but still below longer-term trend levels. Valuation offers limited support due to negative earnings (negative P/E) and no dividend yield.
Positive Factors
Debt-free balance sheet
No reported debt materially reduces ongoing interest burden and financial distress risk, giving management flexibility to prioritize R&D spending and licensing strategy. This durable conservatism supports the company through multi-quarter clinical development cycles without immediate solvency pressure.
Negative Factors
Revenue collapse
A move to zero revenue eliminates internal validation of commercial routes and removes any offset to R&D and G&A costs. For an early-stage biotech, absent revenue increases dependency on external capital, raising dilution and slowing development cadence over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt materially reduces ongoing interest burden and financial distress risk, giving management flexibility to prioritize R&D spending and licensing strategy. This durable conservatism supports the company through multi-quarter clinical development cycles without immediate solvency pressure.
Read all positive factors
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.37M
Dividend YieldN/A
Average Volume (3M)97.01K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth-100.00%
EPS Growth-31.21%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent be...
How the Company Makes Money
null...
Invion Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 3.69M | 4.10M | 3.29M | 2.33M |
| Gross Profit | -1.59M | -1.29M | 1.00M | 1.21M | 969.12K | 810.50K |
| EBITDA | -5.16M | -4.00M | -4.57M | -965.37K | -1.82M | -1.29M |
| Net Income | -10.50M | -8.81M | -5.63M | -1.61M | -2.24M | -1.48M |
Balance Sheet | ||||||
| Total Assets | 8.09M | 9.49M | 15.45M | 19.05M | 20.04M | 5.64M |
| Cash, Cash Equivalents and Short-Term Investments | 137.54K | 850.37K | 783.53K | 4.08M | 8.47M | 1.04M |
| Total Debt | 627.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.38M | 1.24M | 1.01M | 650.63K | 462.41K | 851.50K |
| Stockholders Equity | 5.71M | 8.25M | 14.44M | 18.40M | 19.58M | 4.79M |
Cash Flow | ||||||
| Free Cash Flow | -2.61M | -2.97M | -3.30M | -4.39M | -8.36M | 417.98K |
| Operating Cash Flow | -2.61M | -2.97M | -2.40M | -1.81M | -1.11M | 417.98K |
| Investing Cash Flow | -22.68K | 0.00 | -900.00K | -2.58M | -7.25M | 0.00 |
| Financing Cash Flow | 2.04M | 3.04M | 0.00 | 15.80M | 15.80M | 0.00 |
Invion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$51.26M | -116.67 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$4.37M | -0.30 | -150.48% | ― | -100.00% | -31.21% | |
42 Neutral | AU$7.61M | -0.60 | -110.74% | ― | ― | 49.10% | |
42 Neutral | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% | |
41 Neutral | AU$18.09M | -3.08 | -29.05% | ― | 6.14% | -20.00% | |
40 Underperform | AU$4.66M | -0.29 | 118.54% | ― | 17.56% | 75.11% |
* Healthcare Sector Average
AU:IVX
Invion
0.04
-0.05
-56.99%
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:RGT
Argent Biopharma
0.04
-0.05
-53.49%
AU:MVP
Medical Developments International Limited
0.46
-0.21
-31.06%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-28.57%
AU:IDT
IDT Australia Limited
0.04
-0.03
-36.23%
Invion Corporate Events
Invion strengthens clinical leadership and expands Photosoft into new cancer and eye indications
Jul 31, 2026
Invion reported a modest improvement in quarterly cash reserves to $592,000, supported by expected RD tax incentive receipts and disciplined spending on research and corporate costs. The company also disclosed related‑party payments of $66,0...
Invion Issues New Tranches of Unquoted Options to Strengthen Capital Structure
Jun 22, 2026
Invion Limited has notified the market of the issuance of new unquoted options as part of its ongoing equity arrangements. The company lodged an Appendix 3G detailing these securities, which are not intended to be quoted on the ASX, underscoring i...
Invion Seeks ASX Quotation for New Series of Options
Jun 22, 2026
Invion Limited has applied for quotation on the ASX of 1,564,508 options, designated as IVXO and expiring on 30 June 2027, with an issue date of 19 June 2026. The options form part of a previously announced transaction, indicating Invion is progre...
Invion boosts PDT push with appointment of global clinical leader Colin Hopper
Jun 21, 2026
Invion has appointed Dr Colin Hopper, a globally recognised leader in photodynamic therapy and president of the International Photodynamic Association, as Clinical Advisor to support development of its Photosoft NGPDT platform. Hopper will guide c...
Invion boosts director equity stake with new incentive options
Jun 19, 2026
Invion has disclosed a change in director Alistair Bennallack’s interests following the issue of new incentive options and options in lieu of directors’ fees, as approved at the company’s annual general meeting on 29 May 2026. Be...
Invion Issues 671,882 Unquoted Convertible Notes as Part of Funding Strategy
Jun 16, 2026
Invion Limited has notified the market of the issue of 671,882 unquoted convertible notes, designated under ASX security code IVXAAQ, effective 16 June 2026. The new securities form part of previously flagged capital arrangements and are not inten...
Invion secures strong shareholder backing for capital measures at EGM
May 29, 2026
Invion shareholders have strongly backed a suite of capital and transaction resolutions at an extraordinary general meeting, including approval of a proposed transaction and the issue of consideration shares. The voting outcomes, with support gene...
Invion corrects director shareholding disclosure in ASX filing
May 11, 2026
Invion Limited has disclosed that an indirect shareholding of director Alistair Bennallack, held via a superannuation fund, was omitted from earlier director interest notices lodged in 2020 and 2025, and has now filed a corrected Appendix 3Y with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.